Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
Genzyme Corp. announced top-line data from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer
liquid, an investigational, non-antibiotic , polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
...in May and June 2006.
(9) Includes charges totaling $(5,735)K recorded in December 2007 to write off costs associated with the manufacture of tolevamer
at our manufacturing facilities in Ireland and the United Kingdom.
(10) All periods except for the three months and year ended December 31, ...